QualityStocks would like to highlight
Cannabics Pharmaceuticals, Inc. (
OTCQB: CNBX), founded in 2012 by a team of experts in the fields of molecular biology, cancer research, and pharmacology, who recognized the potential of cannabinoid-based therapies for debilitating and incurable ailments. Through the course of its research, the company’s pharmacology team has amassed valuable knowledge in the development of advanced delivery systems for active cannabinoids that provide improved treatment options for patients wishing to utilize the unique medical properties of the cannabis plant.
In the company’s news,
Cannabics Pharmaceuticals is benefitting from active Israeli government support of the therapeutic cannabis industry. When you hear the words “medical marijuana” your mind is more likely to drift to California than Israel, but the medical marijuana industry in this small Mediterranean country is booming. Unlike in the United States, medical marijuana is legal nationwide in Israel and is estimated to be a $40 million industry with considerable growth.
The Israeli government plays a vital role in the industry’s growth and potential, supporting the research for breakthrough cannabis therapies. Cannabics Pharmaceuticals is taking advantage of this backing and is currently preparing to launch a series of clinical studies in Israel where the company’s research and development division is strategically located. Just last week Cannabics received Government Certification from the Ministry of Health, enabling the company to move forward with its plans to begin advanced laboratory medical research dedicated to cannabinoid science.
Through the course of its own research to date, the company’s pharmacology team has amassed valuable knowledge in the development of advanced delivery systems for active cannabinoids that provide improved treatment options for physicians and patients wishing to utilize the unique medical properties of the cannabis plant.
With an aim of being one of the first and few companies to commercialize clinically tested cannabis-based medical products, Cannabics is developing cannabinoid-based anti-cancer therapies starting with its Cannabics SR capsules. The capsules contain a pure concentrate of cannabinoids derived from select cannabis strains. In observational studies, these IP pending medical cannabis capsules provided beneficial therapeutic effects for 10-12 hours upon a single oral administration.
Cannabics will utilize its new laboratory to continue its advanced research program to demonstrate cannabinoids’ potential as a viable source of anti-cancer therapies.
“The exciting scientific field of cannabinoid research has been largely neglected throughout most of the 20th Century due to a total ban on this field of research,” Cannabics CEO Dr. Zohar Koran stated in an earlier news release announcing the certification. “Thus, the available scientific knowledge regarding active cannabinoids and their mechanisms of action in various disease pathways is dramatically lacking in comparison to other therapeutic fields. There is a huge space of uncharted territory to explore with regards to the potential therapeutic roles of this class of compounds for diverse indications.”
Cannabics’ broader plan is to leverage the vast opportunities for research and development in Israel and launch its SR products under existing medical cannabis regulatory pathways in eligible states of the US and EU markets while simultaneously beginning its clinical studies.
About QualityStocks
QualityStocks, based in Scottsdale, Arizona, is a free service that collects data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters into one Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their investor communication efforts and connecting subscribers with companies that have huge potential to succeed in the short and long-term future.
To sign up for The QualityStocks Daily Newsletter, please visit www.QualityStocks.net
To connect with QualityStocks via Facebook, please visit http://Facebook.com/QualityStocksPage
To connect with QualityStocks via Twitter, please visit http://Twitter.com/QualityStocks
Please read FULL disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.net
Forward-Looking Statement:
This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.
